Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

Fig. 5

“Prime/boost” gene signature from MIS416 Vax + MRB-OVA mapped to ovarian cancer patients from TCGA. a Heat map depicting unique 35 gene signature identified in MIS416 Vax + MRB-OVA treated tumors (n = 8–9). b Hierarchical clustering of ovarian cancer patients from TCGA based on expression of genes identified in a (n = 307). c Ovarian cancer patient survival based on individual clusters identified in b

Back to article page